Simplex Trading’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20K Sell
7,400
-7,000
-49% -$13K ﹤0.01% 7109
2026
Q1
$17.3K Buy
14,400
+10,500
+269% +$12.8K ﹤0.01% 6892
2025
Q4
$3.83K Sell
3,900
-16,500
-81% -$19.8K ﹤0.01% 7562
2025
Q3
$25K Buy
20,400
+16,100
+374% +$17.4K ﹤0.01% 7129
2025
Q2
$4K Sell
4,300
-5,700
-57% -$6.63K ﹤0.01% 7830
2025
Q1
$7K Sell
10,000
-3,000
-23% -$3.68K ﹤0.01% 7314
2024
Q4
$21K Buy
13,000
+11,900
+1,082% +$30K ﹤0.01% 6640
2024
Q3
$3K Sell
1,100
-500
-31% -$1.95K ﹤0.01% 7828
2024
Q2
$5K Sell
1,600
-2,200
-58% -$9.63K ﹤0.01% 7857
2024
Q1
$27K Buy
+3,800
New +$23.5K ﹤0.01% 6836
2023
Q4
Sell
-600
Closed -$1K 9074
2023
Q3
$1K Buy
600
+300
+100% +$994 ﹤0.01% 8294
2023
Q2
$1K Sell
300
-1,000
-77% -$5.52K ﹤0.01% 8610
2023
Q1
$7K Sell
1,300
-8,600
-87% -$51.9K ﹤0.01% 7812
2022
Q4
$99K Buy
9,900
+3,500
+55% +$65.7K ﹤0.01% 5086
2022
Q3
$143K Buy
6,400
+3,000
+88% +$86.7K ﹤0.01% 5034
2022
Q2
$84K Sell
3,400
-3,600
-51% -$99.3K ﹤0.01% 5795
2022
Q1
$271K Buy
7,000
+6,300
+900% +$244K ﹤0.01% 4694
2021
Q4
$40K Sell
700
-3,600
-84% -$204K ﹤0.01% 7529
2021
Q3
$405K Sell
4,300
-100
-2% -$7.84K ﹤0.01% 4423
2021
Q2
$381K Buy
4,400
+4,362
+11,479% +$351K ﹤0.01% 4578
2021
Q1
$313K Buy
38
+9
+31% +$862 ﹤0.01% 4094
2020
Q4
$263K Buy
29
+21
+263% +$1.3K ﹤0.01% 4248
2020
Q3
$31K Sell
8
-319
-98% -$11.1K ﹤0.01% 6040
2020
Q2
$1.12M Sell
327
-258
-44% -$7.69K ﹤0.01% 2039
2020
Q1
$1.3M Sell
585
-179
-23% -$4.53K ﹤0.01% 1648
2019
Q4
$1.5M Buy
764
+233
+44% +$3.7K ﹤0.01% 1738
2019
Q3
$824K Buy
531
+356
+203% +$6.82K ﹤0.01% 2128
2019
Q2
$355K Sell
175
-15
-8% -$270 ﹤0.01% 2903
2019
Q1
$333K Sell
190
-19
-9% -$300 ﹤0.01% 3083
2018
Q4
$268K Buy
209
+54
+35% +$753 ﹤0.01% 2841
2018
Q3
$252K Sell
155
-18
-10% -$213 ﹤0.01% 3381
2018
Q2
$196K Buy
173
+7
+4% +$77 ﹤0.01% 3512
2018
Q1
$62K Buy
+166
New +$1.59K ﹤0.01% 2215

Other funds holding FATE

Simplex Trading's FATE Position: Q2 2026 in Review

Simplex Trading reduced its Fate Therapeutics (FATE) stake by 70% in Q2 2026, selling an estimated $21.4K and leaving 4,866 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7465.

Simplex Trading first reported a position in FATE in Q3 2017 and has held it in 28 quarters since. The position peaked at $770K in Q3 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Simplex Trading held 4,866 shares of Fate Therapeutics worth $13.1K as of Q2 2026.
  • Simplex Trading sold 11,570 Fate Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Fate Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7465 holding.
  • Simplex Trading first reported a position in Fate Therapeutics in Q3 2017 and has held it in 28 quarters since.
  • Simplex Trading's Fate Therapeutics position peaked at $770K in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.